The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

Results showed that the CIC and flu vaccines generated “robust immune responses” across three flu strains (H1N1, H3N2 and B) ...

US biotech Novavax (Nasdaq: NVAX) has reported that its experimental combination COVID-19 and influenza vaccine generated ...

Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 2:00 PM ETCompany ParticipantsJames Patrick Kelly ...

Novavax (NasdaqGS:NVAX) recently reported initial results from its Phase 3 trial for its COVID-19-Influenza Combination and seasonal influenza vaccines, which showed immune responses comparable to ...

COVID-19-influenza combination (CIC) and stand-alone trivalent hemagglutinin nanoparticle seasonal influenza (TNIV) phase 3 ...

Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines generated a strong immune response in ...

Novavax's combo and standalone flu vaccines showed strong immune responses and good safety in a Phase 3 trial of adults 65 ...

The FDA is adopting a new regulatory framework that will change the criteria for approval of COVID-19 vaccines.

(NVAX) on Wednesday said that its COVID-19-Influenza combination and stand-alone Influenza vaccine candidates demonstrated a ...

The Gaithersburg, Md., biotechnology company said Wednesday that results of the initial cohort of vaccines showed both the Covid-19-influenza combination and flu-vaccine candidates induced immune ...